What does CREDOPHAR do?

CREDOPHAR is a wholesaler in Gent. Private Limited, started on 16 October 2012, 1 establishment.

What is the address of CREDOPHAR?

The registered office of CREDOPHAR is located at Kortrijksesteenweg 1091 box B, 9051 Gent.

Is CREDOPHAR still active?

Yes. According to the CBE (29 October 2026) CREDOPHAR is active, legal situation “Normale toestand”, started on 16 October 2012.

Is CREDOPHAR registered on Peppol?

Yes, CREDOPHAR is registered on the Peppol network with ID 0208:0849730193.

What is the enterprise number of CREDOPHAR?

The enterprise number of CREDOPHAR is BE0849730193.

When was CREDOPHAR founded?

CREDOPHAR was founded on 16 October 2012.

Who are the directors of CREDOPHAR?

According to the 2025 annual accounts, the directors of CREDOPHAR are: Aquitania BV, MD Consult BV.

Is CREDOPHAR a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 October 2012; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did CREDOPHAR make in 2025?

CREDOPHAR posted a profit after taxes of € 51,670 in financial year 2025.

What is the revenue of CREDOPHAR?

As a small company, CREDOPHAR is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 257,722.

How much does an employee at CREDOPHAR earn?

The average wage cost per full-time employee at CREDOPHAR was € 93,300 in 2022: staff costs of € 438,290 for 4.7 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

Does CREDOPHAR have a website?

Yes, CREDOPHAR has a website at credophar.be.

CREDOPHAR (Private Limited) - Gent - BE0849730193

Dossier CREDOPHAR, printed on 29 October 2026 from databakkes.be/en/0849730193/credophar. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 19 % of short-term debt in 2025; threshold 65 %.
Busy address KBO

20 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

CREDOPHAR from Gent, company number BE0849730193, closed financial year 2025 with a result of € 51,670 after tax. For that financial year CREDOPHAR recorded a gross margin of € 257,722 and equity of € 1.9 million. Compared with financial year 2024, the result moved from € -182,309 to € 51,670. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 26, 2026.

What it is worth Growing

€ 1.9 million

▲ 3% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 51,670

▲ still € 182,309 loss in 2024

Profit after tax over the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.9 million.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 104,292

▼ 59% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 50,460

▼ 26% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 1,111,605 Gross margin 2022: € 1,111,605 First fiscal year in the series	€ 514,412 Gross margin 2023: € 514,412 ▼ 54% vs 2022 (€ 1,111,605) Unfavourable step	€ 109,990 Gross margin 2024: € 109,990 ▼ 79% vs 2023 (€ 514,412) Unfavourable step	€ 257,722 Gross margin 2025: € 257,722 ▲ 134% vs 2024 (€ 109,990) Favourable step	▲ 134%
Profit after taxes	€ 320,180 Profit after taxes 2022: € 320,180 First fiscal year in the series	€ 200,688 Profit after taxes 2023: € 200,688 ▼ 37% vs 2022 (€ 320,180) Unfavourable step	€ -182,309 Profit after taxes 2024: € -182,309 ▼ € 382,997 vs 2023 (€ 200,688) Unfavourable step	€ 51,670 Profit after taxes 2025: € 51,670 ▲ € 233,979 vs 2024 (€ -182,309) Favourable step	▲ € 233,979
Equity	€ 1,860,471 Equity 2022: € 1,860,471 First fiscal year in the series	€ 2,061,159 Equity 2023: € 2,061,159 ▲ 11% vs 2022 (€ 1,860,471) Favourable step	€ 1,878,850 Equity 2024: € 1,878,850 ▼ 9% vs 2023 (€ 2,061,159) Unfavourable step	€ 1,930,520 Equity 2025: € 1,930,520 ▲ 3% vs 2024 (€ 1,878,850) Favourable step	▲ 3%
Total debts	€ 6,649,039 Total debts 2022: € 6,649,039 First fiscal year in the series	€ 5,572,052 Total debts 2023: € 5,572,052 ▼ 16% vs 2022 (€ 6,649,039) Favourable step	€ 5,761,601 Total debts 2024: € 5,761,601 ▲ 3% vs 2023 (€ 5,572,052) Unfavourable step	€ 5,910,208 Total debts 2025: € 5,910,208 ▲ 3% vs 2024 (€ 5,761,601) Unfavourable step	▲ 3%
Cash	€ 1,086,341 Cash 2022: € 1,086,341 First fiscal year in the series	-	-	-
Retained profit	€ 1,839,950 Retained profit 2022: € 1,839,950 First fiscal year in the series	€ 2,040,638 Retained profit 2023: € 2,040,638 ▲ 11% vs 2022 (€ 1,839,950) Favourable step	€ 1,858,328 Retained profit 2024: € 1,858,328 ▼ 9% vs 2023 (€ 2,040,638) Unfavourable step	€ 1,909,998 Retained profit 2025: € 1,909,998 ▲ 3% vs 2024 (€ 1,858,328) Favourable step	▲ 3%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 66 Bank debt 2023: € 66 Unchanged (€ 0) Unfavourable step	€ 0 Bank debt 2024: € 0 ▼ 100% vs 2023 (€ 66) Favourable step	€ 0 Bank debt 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 8,509,511 Balance sheet total 2022: € 8,509,511 First fiscal year in the series	€ 7,633,211 Balance sheet total 2023: € 7,633,211 ▼ 10% vs 2022 (€ 8,509,511) Unchanged	€ 7,640,451 Balance sheet total 2024: € 7,640,451 Unchanged (€ 7,633,211) Unchanged	€ 7,840,727 Balance sheet total 2025: € 7,840,727 ▲ 3% vs 2024 (€ 7,640,451) Unchanged	▲ 3%
Employees (FTE)	4.7 Employees (FTE) 2022: 4.7 First fiscal year in the series	-	-	-

Key figures of CREDOPHAR, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CREDOPHAR?

What happened at CREDOPHAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 26, 2026 New annual accounts for financial year 2025: profit of € 51,670. filed late Source: NBB ↗
2026 Aquitania BV stepped down as director. NBB
2026 MD Consult BV stepped down as director. NBB
2021 Aquitania BV became a director. NBB
2021 MD Consult BV became a director. NBB
Oct 30, 2012 New establishment in Gent. KBO
Oct 16, 2012 Start of the company according to the CBE. KBO

In short

From € 320,180 profit in 2022 to € 51,670 profit in 2025.

Paid € 266,581 in corporate taxes since 2022.

Best year ever: 2022, with € 320,180 profit.

On average € 236,500 of value added per employee in 2022.

Original PDFs at the National Bank ↗

Management

Ceres Pharma 100%

The stake of Ceres Pharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

CREDOPHAR

Labophar 100%

The shares are held by Ceres Pharma (100%). It owns 100% of Labophar itself.

Directors

According to the 2025 annual accounts

Aquitania BV

Director · represented by Anja Imschoot

Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, b+pharma Belgium, DGPharma, Labophar, 2PHARMA HOLDING, MD Pharma, GLOBIFER INTL +1 more

since 2021 · until 2026

MD Consult BV

Director · represented by Mario Debel

Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, 2PHARMA HOLDING, MD Pharma, Azur Medical, AUGMENTED ANATOMY, GLOBIFER INTL, 2PHARMA

since 2021 · until 2026

Shareholders

Ceres Pharma

100%

Participations

Labophar

100%

Establishments

Establishment units

Physical locations of this company

Registered office

Kortrijksesteenweg 1091 box B

9051 Gent

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.

All companies at this address →

Ceres Pharmaceuticals same network

€ 14.6 million revenue · 2025

What's Cooking Group

KOUTERLOS

€ 55,337 gross margin · 2024

b+pharma Belgium same network

€ 287,023 gross margin · 2025

DGPharma same network

€ 94,120 gross margin · 2024

+15 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS credophar.be

Canonical: https://ceres-pharma.com/nl

About

Technologies

Anime.jsGoogle Tag ManagerNginxSlickjQueryunpkg

Hosting & Email

Email provider

Microsoft 365

Hosting

COMBELL-AS, BE

Website info

HTTPS Ja

Languages EN, FR, NL

Features

Ads Contact page

Security

✓ HTTPS

✓ SPF

✓ DMARC

Details

Company number

0849.730.193

VAT number

BE 0849.730.193

Registered office

Kortrijksesteenweg 1091 bus B, 9051 Gent

Names & denominations

CREDOPHAR

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

16 October 2012

Peppol

Active · Active since 17 Jul 2025

Contact

credophar.be [email protected]

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Handelsbemiddeling in de groothandel in andere specifieke goederen

View on CBE Public ↗ Annual accounts (NBB) ↗

CREDOPHAR

Warning lights

Financials

What happened to CREDOPHAR?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Website

Technologies

Hosting & Email

Website info

Features

Security

Details

Frequently asked questions